FDA Informed Consent Guidance: The "Key Information" and Facilitated Understanding Revolution

For decades, the informed consent document in clinical trials has undergone a slow, bureaucratic transformation. What began as a simple tool to respect patient autonomy has evolved into a massive, 20-page legal disclaimer designed more to protect institutions and sponsors from litigation than to educate the participant.

When documenting informed consent in clinical trials of drugs biologics and devices, this "data dump" approach creates a severe clinical problem: patients routinely sign forms without understanding the actual risks or protocol requirements.

To address this, the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) have steadily updated their regulatory guidance. The most critical shift is the joint March 2024 Draft Guidance, "Key Information and Facilitating Understanding in Informed Consent," which mandates a paradigm shift in how information is structured and presented.

This guide breaks down the required elements of informed consent, reviews the latest FDA/OHRP updates, and explains how clinical trials can implement interactive, tiered electronic consent (eConsent) to achieve absolute regulatory compliance.

#The Required Elements of Informed Consent (21 CFR 50.25)

Before a participant can be enrolled in an FDA-regulated clinical investigation of a drug, biologic, or medical device, the investigator must obtain legally valid informed consent. Under 21 CFR 50.25, the consent document must contain the following core elements:

1. Research Statement: A clear statement that the study involves research, explaining the purpose of the research, the expected duration of the subject's participation, and the specific clinical procedures to be followed.
2. Foreseeable Risks: A description of any reasonably foreseeable risks, discomforts, or potential adverse events associated with the experimental intervention.
3. Expected Benefits: A description of any benefits to the subject or to others that may reasonably be expected from the research.
4. Alternative Treatments: A disclosure of appropriate alternative procedures or courses of treatment that might be advantageous to the subject.
5. Confidentiality of Records: A statement describing the extent to which confidentiality of records identifying the subject will be maintained.
6. Compensation and Injury Support: For research involving more than minimal risk, an explanation as to whether any compensation and any medical treatments are available if injury occurs.
7. Contact Details: An explanation of whom to contact for answers to pertinent questions about the research and subjects' rights, and whom to contact in the event of a research-related injury.
8. Voluntary Participation: A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits, and the subject may discontinue participation at any time.

The live, interactive template below displays a fully compliant, FDA-regulated clinical trial consent layout incorporating all required elements. You can fill, review, and print a copy:

Informed Consent for Participation in an Interventional Clinical Trial

Patient Informed Consent Documentation

Study and Participant Information

Research Institution / Sponsor

Principal Investigator

Participant Full Legal Name

Date of Birth

Full Study Title

ClinicalTrials.gov Identifier (NCT Number)

IRB Protocol Number

Reviewing IRB / Ethics Committee

Clinical Trial Phase

IRB Approval Date

Participant Email Address

Participant Phone Number

Study Coordinator Contact Phone

Study Coordinator Contact Email

Voluntary Nature of Participation

Your participation in this research study is completely voluntary. You may choose not to participate, and if you agree to participate, you may withdraw your consent and stop participating at any time without penalty or loss of any benefits to which you are otherwise entitled. Your decision to participate or not will not affect your current or future medical care at this institution. Withdrawing from the study will not affect your legal rights. In the event of withdrawal, the study team may need to retain and analyze data already collected from you if required by the regulatory protocol or the IRB.

Purpose and Background of the Research

You are being invited to participate in a research study to evaluate [the safety and efficacy of an investigational drug/device/intervention as specified in the study protocol]. Research studies are conducted to generate evidence about whether new treatments, devices, or approaches are safe, effective, and better than existing options. Clinical trials progress through phases: Phase I studies primarily assess safety and dosing in small groups; Phase II studies evaluate preliminary efficacy and safety in larger groups; Phase III studies compare the new treatment to existing standard-of-care treatment in large, randomized, controlled populations; Phase IV studies monitor long-term safety after regulatory approval. You are invited to participate in a Phase [X] study, meaning [the study team should describe the specific context of this phase].

Randomization and Blinding

This study is a randomized controlled trial. If you agree to participate, you will be randomly assigned (like a coin toss) by a computer to one of the study arms: (1) the experimental treatment group, which receives the investigational drug/device; or (2) the control group, which receives [the current standard treatment / an active comparator / a placebo (inactive substance)]. You will have an approximately equal chance of being assigned to either group. This study [is / is not] double-blinded: [In a double-blind study, neither you nor the study team members know which treatment you are receiving until the study code is broken at the pre-specified analysis time. / You and/or the study team will know which treatment you are receiving.] Randomization and blinding are essential to ensure that the study results reflect the true effect of the treatment and are not influenced by expectation or bias.

Study Procedures and Time Commitment

Screening visit: medical history review, physical examination, laboratory tests, ECG, and imaging as specified in the protocol, to confirm eligibility criteria.

Investigational treatment administration: study drug or device delivered on the schedule specified in the protocol (e.g. daily oral tablet, weekly IV infusion, single-device implant).

Follow-up visits: scheduled clinic visits at defined intervals for safety assessments, blood and urine tests, questionnaires, and imaging scans as per the protocol visit schedule.

Patient diary: daily electronic or paper diary recording symptoms, medication use, and adverse events as instructed by the study team.

Total time commitment: estimated [X] hours over [Y] weeks/months of active participation plus [Z] months of long-term safety follow-up.

Foreseeable Risks and Discomforts

Risks of the investigational drug or device: [The study team must insert the specific known and potential risks based on preclinical data and Phase I/II experience as listed in the Investigator's Brochure and protocol, e.g.: nausea, fatigue, elevated liver enzymes, specific organ toxicities, known adverse drug reactions].

Risks of the study procedures: phlebotomy-related bruising, discomfort, or haematoma from frequent blood draws; low-dose radiation exposure from protocol-required CT scans; risks specific to any invasive procedure (biopsy, lumbar puncture) required by the protocol.

Potential unknown risks: because the investigational agent is new, there may be unforeseen risks not identified in preclinical or earlier-phase studies. New safety information identified during the study will be disclosed to all participants promptly.

Placebo risk: participants assigned to the control or placebo arm will not receive the investigational treatment during the blinded phase. If the investigational treatment proves effective, delayed access to it may be a disadvantage.

Reproductive risk: the investigational drug may be harmful to a developing fetus or infant. Women of childbearing potential must use two forms of highly effective contraception for the duration of the study and for [X] months following the last dose. Breastfeeding is not permitted during study participation.

Potential Benefits

There may be no direct medical benefit to you from participating in this study. The investigational treatment may or may not improve your condition; this is precisely what the study is designed to determine. The knowledge gained from this study may benefit future patients with this condition. The information collected about your health through study visits and tests may be of indirect benefit by enabling closer monitoring of your condition during the study period.

Confidentiality and Data Privacy (HIPAA Authorization)

Your participation in this study and your personal health information will be kept confidential to the extent permitted by law. Study records will be identified only by a participant code number. Your identifying information will be kept in a separate, locked file accessible only to the study team. The study sponsor, the IRB, and regulatory authorities (FDA, EMA) may inspect study records. A Certificate of Confidentiality from the [relevant federal agency] protects identifiable research information from compelled disclosure in civil, criminal, or administrative proceedings. Research data will be retained for a minimum of 15 years following study completion as required by federal regulations.

HIPAA Authorization for Research Use of Protected Health Information

By signing this consent form, you are also authorizing the study team to access, use, and disclose your Protected Health Information (PHI) as defined under HIPAA for the purposes of conducting this clinical trial. The information that may be used or disclosed includes: medical history, laboratory results, imaging reports, physical examination findings, and any other health data relevant to the study protocol. Authorized recipients of your PHI include: the study sponsor (and its agents), the IRB, regulatory agencies (FDA, EMA), and study monitoring bodies. You have the right to revoke this authorization at any time in writing; however, revocation will not affect uses already made during your participation. Your refusal to authorize use of your PHI will result in your ineligibility for this study.

Compensation and Study Costs Summary

Compensation: [Specify: e.g. no compensation / $X per completed visit / travel reimbursement up to $X]. All study-required procedures, laboratory tests, and investigational drugs provided as part of this trial will be at no cost to you. Standard-of-care procedures that would be performed regardless of study participation may be billed to your insurance. Any injury directly caused by study procedures will be treated at no cost to you. Compensation for study-related injuries beyond treatment costs is not available unless otherwise specified by the sponsor. If you believe you have been injured as a result of this research, contact [Study Injury Contact].

Right to Withdraw Without Penalty

Your participation in this clinical trial is entirely voluntary. You may withdraw at any time for any reason without penalty, loss of benefits to which you are otherwise entitled, or adverse effect on your relationship with the clinical team. Withdrawal from the study will not affect your access to standard medical care. If you withdraw, any data or samples collected before withdrawal may be retained and used in the study analysis unless you specifically request their destruction in writing.

Language Access and Interpreter Services

If English is not your primary language or if you have difficulty reading, a qualified interpreter is available to translate this document or read it aloud to you at no cost. The IRB-required short form process for non-English speakers will be followed if applicable. Please notify the study coordinator before signing this document.

Copy of Consent Acknowledgment

Federal regulations (21 CFR 50.27 and 45 CFR 46.117) require that you receive a signed copy of this informed consent document. I acknowledge that I have received a copy of this signed consent form for my own records.

Participant Authorization

I confirm that I have read or had read to me this consent form. All my questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I understand I may withdraw at any time without penalty. I authorize the use and disclosure of my health information for the purposes of this study as described above.

Signatures and Verification

Participant / LAR Signature

Relationship (if LAR)

Principal Investigator / Delegated Researcher Signature

Witness Signature (if required by IRB)

Date and Time of Consent

Consent Form Version Date Used

Print / Save PDF Customize in Free Builder

While these required elements have been standard for years, the way they are presented has historically failed to achieve their primary goal: actual participant comprehension.

#The Core Problem: The "Data Dump" and Legal Boilerplate

Traditional paper consent forms often present the required elements as a long, continuous wall of text written in dense, academic, and legalistic language.

When a clinical coordinator hands a prospective trial participant a 25-page paper binder, the participant is hit with a massive volume of information. Due to cognitive overload, they rarely read the entire document. Instead, they scan the text, sign the signature line, and remain largely unaware of key protocols—such as required clinic visit frequencies, critical drug interactions, or severe side effects.

This lack of understanding is a massive risk. If a patient experiences an unexpected side effect that they did not realize was possible, they are much more likely to drop out of the trial or, in worst-case scenarios, file a malpractice claim. Furthermore, institutional review boards (IRBs) and FDA inspectors are increasingly scrutinizing sites that cannot demonstrate a robust, documented consent process.

#The 2024 Regulatory Shift: "Key Information" and Facilitated Understanding

To resolve the data dump crisis, the 2018 Common Rule revision introduced a new requirement: the consent document must begin with a "Key Information" section.

In March 2024, the FDA and OHRP jointly released draft guidance specifically detailing how to build this section. The guidance emphasizes that the "Key Information" page should not just be a summary of the form, but must actively "facilitate understanding."

#Key Recommendations from the March 2024 Guidance:

• Concise and Focused: The Key Information section must be brief (ideally limited to a single page or a few digital screens) and focus on the elements most likely to assist a patient in making a decision.
• Comprehensibility First: The text must be written at an appropriate reading level (typically 8th-grade level or lower) and avoid complex medical jargon.
• Tiered Information Design: The guidance strongly supports the use of "tiered consent," where high-level key facts are presented first, with the ability for patients to click or scroll to expand detailed sections as needed.
• Multimedia and Visual Elements: For the first time, federal regulators explicitly recommend using multimedia—such as diagrams, videos, summary tables, and hover-over definitions—to explain complex concepts like randomization, treatment arms, or device mechanics.

#Implementing Tiered eConsent with ConsentCollect

Specialized electronic consent platforms are uniquely positioned to meet these new FDA mandates. While paper forms cannot be "tiered" or incorporate multimedia, digital form builders make this process seamless.

#How ConsentCollect Facilitates Understanding:

1. Structured "Key Information" Screens: Instead of presenting a continuous PDF, the ConsentCollect builder structures the consent flow into a series of bite-sized, card-style screens. The first screen presents the concise "Key Information" summary, ensuring immediate compliance with the 2018 Common Rule and the March 2024 guidelines.
2. Interactive Tooltips and Explanations: Hard-to-understand clinical jargon (e.g., pharmacokinetics, double-blind, biopsies) can be embedded with interactive hover tooltips. When a participant taps on the word, a simple, patient-friendly definition pop-up appears, providing immediate clarity without cluttering the main page.
3. Embedded Visuals and Videos: Sponsors can insert brief educational videos explaining study requirements or clinical device instructions directly into the consent flow, ensuring visual learners comprehend the study procedures.
4. Real-Time Comprehension Checks: Rather than assuming a patient understood the risks, ConsentCollect allows sites to embed simple, non-graded understanding questions throughout the flow. If a patient answers incorrectly, the system automatically redirects them to the relevant section for review, documenting an active, verifiable comprehension process.

#Operational Impact: Streamlining Site Workflows

Adopting a digital-first, pre-validated eConsent platform does not just improve patient understanding and protect compliance—it also solves massive site headaches.

• Version Control: When protocols change, updating paper forms requires printing new packets, discarding old ones, and manually tracking version numbers. ConsentCollect automates version control, ensuring sites always display the IRB-approved version, preventing the common audit error of signing an outdated consent form.
• Remote Enrollment: Under the FDA's guidelines for hybrid and decentralized clinical trials (DCTs), eConsent allows patients to review materials, consult with family, and sign forms securely from home, dramatically accelerating enrollment rates and trial accessibility.

#Frequently Asked Questions

#What are the required elements of informed consent in clinical trials of drugs biologics and devices?

Under FDA regulation 21 CFR 50.25, the 8 required core elements are: a statement explaining that the study involves research, purposes, duration, and procedures; descriptions of foreseeable risks; expected benefits; alternative procedures or treatments; details on data confidentiality; medical treatment and compensation details for research-related injuries; contact details for participant rights and injuries; and a statement that participation is voluntary.

#What does the March 2024 FDA draft guidance on informed consent require?

The March 2024 draft guidance, jointly issued by the FDA and OHRP, mandates that consent documents begin with a concise, easy-to-understand "Key Information" summary. The guidance strongly advocates for using tiered information structures (short summaries backed by expandable details) and interactive digital aids (videos, tooltips, diagrams) to replace text-heavy PDFs.

#How does electronic consent (eConsent) improve patient understanding in clinical trials?

Unlike paper forms that present a dense wall of legal boilerplate, eConsent platforms break content into bite-sized screens. They allow sponsors to embed interactive tooltips for medical jargon, display short educational videos, and include real-time comprehension checks (quizzes) to ensure participants actually understand study protocols before signing.

#Can a sponsor update a clinical trial consent form without invalidating existing signatures?

Yes. A compliant eConsent platform manages updates through automated version control. When a protocol modification is approved, the system generates a new version for future signers and re-consenting participants without modifying or corrupting the cryptographic hashes of historically signed documents.

#How does ConsentCollect help sites comply with FDA eConsent guidelines?

ConsentCollect features structured card layouts to enforce the concise "Key Information" summaries required by the Common Rule. It includes interactive tooltips, teach-back comprehension checks, strict sequential signature locking, and local-first encryption to protect patient privacy while logging the detailed telemetry required by FDA regulations.

#Conclusion

The March 2024 FDA/OHRP draft guidance is a clear signal that federal regulators are moving away from traditional, paper-based legal disclaimers. Sponsors who continue to rely on long-form paper documents or static PDFs run the risk of falling behind compliance trends and suffering from higher patient dropout rates.

#Transitioning to an agile, browser-native platform like ConsentCollect makes obtaining informed consent in clinical trials of drugs biologics and devices secure, reliable, and compliant. By utilizing tiered content structure, multimedia aids, and documented comprehension checks, you turn consent from a paper chore into an active, compliant, and patient-centered data asset.